62 results about "Multi resistant bacteria" patented technology

The invention discloses a full D-type antibacterial peptide with high enzymolysis stability and broad-spectrum antibacterial activity and application thereof. The antibacterial peptide is obtained by sequentially and repeatedly arranging D-type tryptophan, D-type arginine and D-type lysine for four times and carrying out C-terminal amidation; the amino acid sequence of the gene is (D-Trp)-(D-Arg)-(D-Lys)-(D-Trp)-(D-Arg)-(D-Lys)-(D-Trp)-(D-Arg)-(D-Lys)-(D-Trp)-(D-Arg)-(D-Lys)-(D-Trp)-(D-Arg)-(D-Lys)-NH2, and is marked as DWRK-12. The antibacterial peptide shows broad-spectrum antibacterial activity and excellent stability, can effectively resist clinically separated multidrug resistant strains, and keeps high cell selectivity at the same time. Due to the characteristics, the antibacterial peptide has important application value in the aspect of developing novel antibacterial drugs, especially in the field of treatment of infection of multiple drug-resistant bacteria.

The invention relates to a Cu2-xSe-Pt nano material, a microneedle patch, a preparation method and application. The Cu < 2-x > Se (at) Pt nano material is composed of a Cu < 2-x > Se nanosphere and platinum modified on the surface of the Cu < 2-x > Se nanosphere in situ. The invention provides a preparation method of a Cu2-xSe-Pt nano-material, which comprises the following steps: adding PSS, SeO2 and AA into water, heating and stirring, adding copper salt and AA, reacting, and adding water and a hexachloroplatinic acid solution to obtain the Cu2-xSe-Pt nano-material. The invention provides an application of a Cu < 2-x > Se (at) Pt nano material. The invention also provides a microneedle patch as well as a preparation method and application thereof. The invention provides a novel material for resisting multi-drug-resistant bacteria, which solves the problems that the existing single antibacterial strategy is limited and the expected curative effect cannot be achieved, also solves the problem of cytotoxicity of the existing nano enzyme, realizes deep drug delivery, ensures efficient local drug release and avoids systemic toxicity.

The invention discloses a multi-drug-resistant bacterium infection risk assessment method, system and device and a storage medium, and belongs to the technical field of medical data analysis, and the method comprises the steps: collecting a clinical related data set of an ICU patient, and carrying out the preprocessing of the clinical related data set to obtain a to-be-assessed data set; performing feature extraction on the to-be-evaluated data set in combination with a long short-term memory network and a time sequence attention mechanism to obtain a high-risk feature set; inputting the high-risk feature set into a pre-constructed dynamic scoring model, and calculating a corresponding risk score through the dynamic scoring model; and grading the risk score based on a preset grading rule to obtain a current risk level, and outputting a corresponding intervention strategy through a preset intervention decision mechanism based on the current risk level. According to the scheme, the high-risk feature set is extracted by combining the long-short-term memory network with the time sequence attention mechanism, then the risk score is calculated through the dynamic scoring model, the risk level is determined according to the preset grading rule, the intervention strategy is output, and the accuracy of MDRO infection assessment is improved.

The invention relates to an antibacterial peptide and application thereof. The amino acid sequence of the antibacterial peptide is as shown in SEQ ID No. 1. The antibacterial peptide has excellent broad-spectrum antibacterial activity, for example, the antibacterial peptide has antibacterial activity on bacteria of the genus Staphylococcus (Staphylococcus), the genus Acinetobacter (Acinetobacter) and the genus Bacillus (Bacillus). Under the background that the global bacterial drug resistance problem is increasingly severe and traditional antibiotics gradually lose efficacy on multi-drug-resistant bacteria, a new treatment means is provided for treating bacteria such as methicillin-resistant staphylococcus aureus, carbapenem-resistant acinetobacter baumannii and bacillus subtilis which bring huge threats to public health. And a new possibility is provided for solving the problem that no medicine can be used clinically.

A novel bacteriophage having bacteriolytic activity against bacteria of the genus Salmonella, such as S. Enteritidis, and a bacteriolytic agent consisting of the same are provided. The bacteriophage and the bacteriolytic agent including the bacteriophage have a wide host range for bacteria of the genus Salmonella. A host-specific bacteriophage and an effective Salmonella bacteriolytic agent consisting of the same are provided. A bacteriophage capable of effectively controlling S. Typhimurium, and in particular, multidrug-resistant S. Typhimurium, and a bacteriolytic agent consisting of the same are also provided. A bacteriophage having a specific genomic DNA sequence; a Salmonella bacteriolytic agent consisting of the bacteriophage; and a composition comprising the same are provided.

The invention discloses application of black phosphorus loaded cerium dioxide composite temperature-sensitive hydrogel in preparation of diabetes wound anti-inflammatory drugs, and relates to the technical field of hydrogel preparation. The black phosphorus-loaded cerium dioxide composite temperature-sensitive hydrogel is used for diabetes wound anti-inflammation, and the preparation method of the black phosphorus-loaded cerium dioxide composite temperature-sensitive hydrogel specifically comprises the following steps that a composite material of black phosphorus nanosheets loaded cerium dioxide nanoparticles is used for preparing the black phosphorus-loaded cerium dioxide composite temperature-sensitive hydrogel, and the black phosphorus-loaded cerium dioxide composite temperature-sensitive hydrogel is used for diabetes wound anti-inflammation. The composite hydrogel with the temperature-sensitive characteristic is jointly prepared from the hydrogel and pluronic F127. The invention further provides application of the black phosphorus loaded cerium dioxide composite temperature-sensitive hydrogel in preparation of diabetes wound anti-inflammatory drugs, antibacterial drugs, antioxidant drugs and arthritis treatment drugs, and the problems that chronic infected wounds are not healed for a long time and multiple drug-resistant bacteria are formed due to abuse of antibiotics are effectively solved.

The invention belongs to the technical field of biomedical materials. The invention provides a composite nano preparation for treating diabetic ulcer and promoting wound healing and a preparation method thereof. The preparation method comprises the following steps: mixing tetra (4-carboxyl phenyl) porphyrin and FeCl3. 6H2O for reaction, then adding a mixed solution composed of benzoic acid and 3, 5-dicarboxyphenylboronic acid for reaction, and then performing centrifugal drying; dispersing in water, adding a chloroplatinic acid solution, stirring, adding a sodium borohydride solution, continuously stirring, and centrifugally drying; stirring with a mixture of curcumin, flavonoid glycoside and astragaloside in ethanol, and carrying out centrifugal drying; and finally, stirring with glucose oxidase in water, and centrifugally drying. The composite nano preparation provided by the invention has an excellent antibacterial effect on multi-drug-resistant bacteria, can effectively destroy a biological membrane, can well treat diabetic ulcer and promote wound healing, and has a relatively good application prospect.

This invention provides a compound drug for treating melioidosis, its preparation method, and its application. The drug comprises active components of traditional Chinese medicine, a bioactive preparation, and a pharmaceutically acceptable carrier. The active components of traditional Chinese medicine are primarily extracts of Scutellaria baicalensis, Coptis chinensis, Fagopyrum dibotrys, and Polygonum cuspidatum. The bioactive preparation includes polymyxin B, homoserine lactonease, and recombinant human β-defensin 3. The components work synergistically to construct a comprehensive intervention system covering all pathological stages, including biofilm disruption, sterilization, anti-endotoxin activity, intracellular bacterial clearance, immune regulation, and tissue repair. This system can effectively disrupt bacterial biofilms, kill multidrug-resistant strains, neutralize endotoxins, and eliminate latent intracellular bacteria, addressing the core pain points of existing melioidosis treatments, such as strong drug resistance, significant toxic side effects, and high recurrence rates. The preparation process of this invention is carried out under low-temperature and sterile conditions throughout, which fully preserves the stability of the active ingredients, making it suitable for industrial production. The drug can be prepared in various dosage forms, covering all clinical subtypes of melioidosis, and possesses clinical application value and promising prospects for widespread application.

The present invention belongs to the medical field, and relates to novel β-lactamase inhibitors, for the treatment of bacterial infections in combination with β-lactam antibiotics, including infection caused by drug resistant organisms and especially multi-drug resistant organisms. The present invention includes compounds according to formula (I): or pharmaceutically acceptable salts thereof, wherein M and R are as defined herein.

This invention relates to the field of bacterial infection treatment technology, and discloses an enzyme-responsive probe, its preparation method, and its applications. The probe of this invention constructs an enzyme-responsive "prodrug" structure by introducing cephalosporin derivative linker units that can be specifically cleaved by β-lactamases onto a hemicyanine optical framework. This structure remains optically and therapeutically inert in normal tissues, but is selectively activated at the site of infection by drug-resistant bacteria. When the probe contacts multidrug-resistant bacteria that overexpress β-lactamases, the linker units undergo enzymatic cleavage, releasing hemicyanine active molecules with near-infrared fluorescence emission and highly efficient photothermal conversion capabilities, achieving high-contrast fluorescence imaging and controllable photothermal sterilization of the infection focus. The probe of this invention has a simple synthetic route, mild conditions, and reliable purification methods, making it suitable for large-scale preparation, especially for the precise diagnosis and targeted photothermal synergistic treatment of superficial tissue infections such as bacterial keratitis.

Composition comprising an antibacterial benzimidazole-pyrazole hybrid compound, N-(1H-Benzo[d]imidazol-2-yl)-1-(3-(4-Fluorphenyl)-1-phenyl-1H-pyrazole-4-yl)methanimin (AJ01), characterized at a minimum inhibitory concentration of 12.5 µg / ml against Staphylococcus aureus, including multi-resistant strains, and with predicted high affinity for bacterial target proteins.

The invention relates to the technical field of natural product extraction and purification and biological medicine, in particular to day lily polysaccharide with broad-spectrum antibacterial activity and application of the day lily polysaccharide. The molecular weight of the hemerocallis citrina polysaccharide is 1959 Da, monosaccharide components of the hemerocallis citrina polysaccharide mainly comprise fructose (88.87%) and glucose (11.13%), and the hemerocallis citrina polysaccharide is high-fructose neutral polysaccharide. The main chain is-> 1)-beta-D-Fruf-(2->), side chains are connected to O-6 sites of partial main chain residues, and the side chains comprise beta-D-Fruf-(2->) and-> 6)-beta-D-Fruf-(2->); the molar percentages of the sugar residues Fruf1, 2, Fruf2, Fruf1, 2, 6, Fruf2, 6 and Glc1, 6 are respectively 41.94%, 23.59%, 9.27%, 16.80% and 8.40%, and the molar percentages of the sugar residues Fruf1, 2, Fruf2, Fruf2, Fruf6 and Glc1, 6 are respectively 41.94%, 23.59%, 9.27%, 16.80% and 8.40%; the hemerocallis citrina baroni polysaccharide shows remarkable bacteriostatic activity on clinically separated multi-drug-resistant strains and standard strains, and shows dose dependence; in addition, the improvement effect of the hemerocallis citrina polysaccharide on the lung tissue injury is enhanced along with the increase of the dosage, the effect can be quantified and repeatable, and the requirements of drug development are met.

The invention discloses an aromatic polyketone compound as well as a preparation method and application thereof. The compound GaB (3) has an effect of treating infection of multiple drug-resistant bacteria. The compound is obtained by being separated from a secondary metabolite of the symbiotic Streptomyces sp.QHH-9511 of licheniformis, and the compound 2, the compound 3, the compound 4 and the compound 5 are new compounds. According to the present invention, the research results show that the GaB can effectively sterilize a variety of drug-resistant bacteria (methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, carbapenem-resistant acinetobacter baumannii, multi-drug-resistant pseudomonas aeruginosa, multi-drug-resistant salmonella, and the like); in addition, the compound has the characteristics of broad-spectrum sterilization, biofilm formation inhibition and low-frequency drug resistance, and can be combined with other antibiotics to cope with super bacteria. Mechanism research shows that GaB is combined with glucosamine-6-phosphate synthetase (GlmS) to prevent synthesis of cell walls so as to play an antibacterial role, and a plurality of constructed living body models show that the compound can effectively reduce the content of bacteria in a body and promote wound repair and has in-vivo medication safety. The research result shows that the GaB can be used as a safe and effective novel pilot natural active small molecule for resisting infection of multiple drug-resistant bacteria.

The invention discloses an external antibacterial medicine composition as well as a preparation method and application thereof, and belongs to the technical field of antibacterial medicines. The external antibacterial pharmaceutical composition provided by the invention comprises a medicinal active component and a pharmaceutically acceptable carrier, wherein the medicinal active component comprises polymyxin B sulfate, trimethoprim sulfate and lidocaine; every 10 g of the antibacterial pharmaceutical composition for external use is prepared from the following components in parts by weight: 40000 to 60000 U of polymyxin B sulfate, 0.08 to 0.16 g of trimethoprim sulfate and 0.30 to 0.35 g of lidocaine. The pharmaceutical composition disclosed by the invention has broad-spectrum inhibition on multiple drug-resistant bacteria such as common gram-negative drug-resistant bacteria and acinetobacter baumannii on a wound surface, synchronously plays a synergistic role in relieving inflammatory response of the wound surface and relieving local pain, and remarkably improves the medication safety and the comprehensive treatment effect while ensuring excellent antibacterial activity.

The invention relates to the technical field of microorganisms, in particular to lactobacillus reuteri with antibiotic post-effect prevention and control and Chinese herbal medicine synergistic interaction functions, the lactobacillus reuteri is named as HBNK11 and is preserved in the China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC M20251479. The lactobacillus reuteri provided by the invention has a remarkable inhibition effect on gram-positive bacteria and gram-negative bacteria, and breaks through the limitation of narrow antibacterial spectrum of traditional probiotics. Meanwhile, the survival rate in simulated gastric juice with the pH value of 2.5 reaches 112.4%, it is ensured that the strain stably survives and plays a role in the strong acid environment of the gastrointestinal tract of livestock and poultry, and the problem that the gastrointestinal tract tolerance of traditional probiotics is poor is solved. When the lactobacillus reuteri is coordinated with a Chinese herbal medicine monomer, the monomer dosage can be reduced by 128 times. The lactobacillus reuteri provides a high-quality resource for developing a novel microbial feed additive, and has important application value for reducing antibiotic dependence in a breeding link and preventing and controlling propagation of multiple drug-resistant bacteria.

This disclosure relates to the crystalline hydrate forms of (S)-2-((R)-6-(N-((1s,3S)-3-amino-cyclobutyl)carbamimidoyl)chroman-2-yl)-2-((((Z)-1-(2-aminothiazol-4-yl)-2-(((S)-2,2-dimethyl-4-oxo-1-(sulfooxy)azetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)propanoic acid, including crystalline hydrate form A, crystalline hydrate form B and crystalline hydrate form D, which are useful as antibiotic agents for the treatment of bacterial infections, such as bacterial infections caused by gram-negative bacteria, including strains that are multidrug resistant.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus johnsonii with a function of resisting multiple drug-resistant bacterium biological membranes and anti-inflammatory activity and application of the lactobacillus johnsonii. The lactobacillus johnsonii A25041 provided by the invention has strong inhibition and anti-biofilm activity on multi-drug-resistant gram-negative bacteria (including escherichia coli, pseudomonas aeruginosa and acinetobacter baumannii) and methicillin-resistant staphylococcus aureus, and the lactobacillus johnsonii A25041 has good acid-base tolerance and gastrointestinal fluid tolerance, so that the lactobacillus johnsonii A25041 can be used for preparing medicines for preventing and treating various diseases. The composition shows excellent anti-inflammatory activity and oxidation resistance, does not have hemolysis capacity, is good in safety, has natural drug resistance to gentamicin, tetracycline, ciprofloxacin, lincomycin and compound sulfamethoxazole, can be used together with antibiotics at the same time or in sequence, maintains intestinal microecological balance and relieves antibiotic burden while exerting the sterilization effect of the antibiotics, and has a good application prospect. The method can be widely applied to functional food development, and has important application value in the field of biological medicine and daily chemical products.

This invention relates to the field of microbial technology, and more particularly to a broad-spectrum Aeromonas hydrophila phage and its applications. The Aeromonas hydrophila phage AhP2505006 is classified as follows: Aeromonas hydrophila Phage AhP2505006, with accession number CCTCC NO: M20251307, exhibits cross-species lytic activity. It can effectively lyse *Aeromonas*, *Vibrio parahaemolyticus* and *Vibrio alginolyticus*, and *Citrobacter freundii*. It also possesses excellent targeting ability against multidrug-resistant strains and broad host spectrum characteristics, achieving a lysis rate of up to 80% against multidrug-resistant *Aeromonas hydrophila*. In the prevention and control of diseases caused by various pathogens, or in practical scenarios facing the limitations of traditional antibiotics and highly specific bacteriophages, it has become a highly promising solution.

This invention relates to an antimicrobial peptide and its applications. The amino acid sequence of the antimicrobial peptide is at least one of the sequences shown in SEQ ID No. 1 to SEQ ID No. 8. The antimicrobial peptide exhibits excellent broad-spectrum antimicrobial activity, for example, against Acinetobacter spp. (…). Acinetobacter ), Pseudomonas aeruginosa ( Pseudomonas aeruginosa ) and Bacillus spp. ( Bacillus This bacterium possesses antibacterial activity. Against the backdrop of increasingly severe global bacterial resistance and the gradual ineffectiveness of traditional antibiotics against multidrug-resistant bacteria, this provides a new treatment option for carbapenem-resistant bacteria such as Acinetobacter baumannii, Pseudomonas aeruginosa, and Bacillus subtilis, which pose a significant threat to public health, and offers new possibilities for solving the clinical dilemma of "no available drugs."

The invention discloses an operation method of a fabric cleaning and disinfecting machine for controlling multiple drug-resistant bacteria, and particularly relates to the technical field of fabric cleaning and disinfecting. Obtaining the pollution intensity grade, the fabric material type and the target strain spectrum information of the target fabric, and constructing a pollution source information set; calling a preset disinfection response parameter model, and determining washing temperature, washing time and disinfectant type and concentration; based on the fabric type and the temperature resistance and chemical resistance of the fabric, a matched cleaning program set is retrieved from a database and dynamically adjusted; the water temperature and the detergent concentration are monitored in real time in the washing process, and washing parameters are adjusted according to the feedback control model; after cleaning is finished, the temperature deviation in the washing stage is extracted and analyzed with the critical inhibiting and killing threshold value of the target strain, and the disinfection response model is updated based on the analysis result; according to the method disclosed by the invention, the efficient killing of multiple drug-resistant bacteria and the self-adaptive optimization of the disinfection process can be realized, and the method is suitable for fabric treatment requirements in the fields of medical treatment, old-age care and public health.

The invention discloses a wound flushing assembly for diabetic foot infection nursing, and relates to the technical field of diabetic foot nursing. A wound surface flushing assembly for diabetic foot infection nursing comprises a supporting rod, the top of the supporting rod is movably connected with an adjusting cylinder in a sleeving mode, a sealing box is fixedly installed at the top of the adjusting cylinder, and a sewage draining pipe is fixedly installed at the bottom of one side of the sealing box. The foot of a patient is isolated from the outside by arranging the sealing structure, an independent debridement space is formed, aerosol containing pathogenic bacteria generated during flushing is prevented from polluting the surrounding environment, the device is particularly suitable for diabetic foot patients infected by multiple drug-resistant bacteria, and the cross infection risk in a hospital is reduced; meanwhile, the stable sealing state can reduce the contact area of the wound surface and air, the oxidation speed of necrotic tissues is delayed, and the debridement environment is kept relatively clean.

Antibiotic compounds having both antibiotic and aggregation-induced emission (AIE) characteristics. The compounds comprise an azole antibiotic unit, for example naphthalimide triazole (NT), and an AIE unit, for example triphenylethylene (TriPE). The compounds act as an effective AIEgen with ROS generating capabilities. The present combinations of an azole antibiotic unit and an AIE unit do not negatively affect the antibacterial properties of the azole. Accordingly, the present compounds exterminate bacteria with both the antibacterial mechanism of the azole along with the ROS produced when the AIE unit is exposed to light. In addition, the intrinsic imagining ability of the present compounds enables them to be used as imaging tools to monitor the drug-bacteria interaction. Collectively, the present compounds provide multiple functions including imaging, monitoring, and bacterial infection inhibition for integrated diagnosis and treatment in clinical practices.

The invention relates to the technical field of antibacterial agents, and discloses a main chain degradable type carbonic ester alternating cation antibacterial agent, the structural formula is shown in the following formulas: R1 is one of the following formulas I-XI, R2 is one of CH2CH2, CH2CH2CH2CH2 and CH2OCH2CH2OCH2, the value range of n1 is 2-7, the value range of m is 3-7, and the value range of n is 10-20. According to the antibacterial agent, a cationic sterilization group and a degradable carbonic ester group are alternately introduced into a polymer main chain, so that accurate construction of a structure is realized. The prepared carbonic ester alternate cationic antibacterial agent has broad-spectrum and efficient activity on clinically separated multi-drug-resistant bacteria, the minimum inhibitory concentration (MIC) can reach 2-8 mu g / mL, degradation products are non-toxic and have no bactericidal activity, and meanwhile, the bacteria are difficult to induce to generate drug resistance.

The invention provides an antibacterial biphenol derivative and a preparation method thereof, and belongs to the technical field of organic synthesis. The amphiphilic target compound with high antibacterial activity is obtained by carrying out structural modification on a biphenol core skeleton, introducing an amido bond to a phenolic hydroxyl site, connecting amino and guanidyl cation groups and simultaneously introducing a biphenylmethyl or n-hexyl hydrophobic side chain. The derivative disclosed by the invention has a remarkable inhibition effect on gram-positive bacteria, gram-negative bacteria and multi-drug-resistant strains. The compound can be widely applied to preparation of antibacterial drugs, medical disinfection preparations and antibacterial functional materials, and has important clinical transformation value in the fields of infectious disease treatment and medical protection.

The invention relates to the technical field of medical equipment, in particular to a disinfecting and drying storage box of a multi-drug-resistant bacterium aerosol inhalation device, which comprises a shell, a drying cavity and a soaking cavity are arranged in the shell, a transmission module is mounted at the center of the drying cavity and the soaking cavity, the transmission module comprises a driving part, and a screw rod is fixedly connected to an output shaft of the driving part. The lead screw is sleeved with a nut seat, a carrier is fixedly connected to the nut seat, and a clamping assembly is installed on the carrier. A high-temperature hot air module is installed on the side wall of the drying cavity, a hydrogen peroxide plasma disinfection module is arranged at the top of the drying cavity, an annular soaking tank is installed at the bottom of the soaking cavity, disinfection soaking liquid is contained in the soaking tank, and a liquid level sensor and a constant-temperature heating piece are arranged on the cavity wall of the soaking tank; a control panel is arranged on the outer side of the shell. The device is used for realizing the integrated treatment of the multi-drug-resistant bacterium aerosol inhalation device from deep soaking disinfection, efficient hot air drying to full-dimensional plasma secondary disinfection.

This invention relates to a Nile Red derivative with photodynamic-photothermal properties, its preparation, and its applications. Two Nile Red derivatives (TPACN and TPAOMCN) were carefully designed and synthesized, with the following structural formulas: Under 660nm laser irradiation, the Nile Red derivatives of this invention can generate a large amount of reactive oxygen species and achieve efficient photothermal conversion, exhibiting powerful photodynamic-photothermal therapeutic effects. They can not only resist multidrug-resistant bacterial infections to promote wound healing but also block the spread of monkeypox virus. The TPAOMCN NFs of this invention can effectively eliminate drug-resistant bacteria in mouse wounds under laser irradiation, regulate inflammatory responses, and promote the healing of infected wounds. In the characteristic pustular lesions of simulated monkeypox, after TPAOMCN NFs combined with laser treatment, the viral titer within the lesions was significantly reduced, the infected lesion tissue was rapidly repaired, and the spread of the virus to healthy mice was effectively blocked, demonstrating great application potential.

The present invention relates to a Nile red-based photosensitizer and its preparation and application. The present invention has developed a series of Nile red-based photosensitizers with the following structural formula: The present invention not only has a profound impact on the structure of the photosensitizer by changing the electron donating ability of the donor, but also has important significance for the generation of active oxygen by the photosensitizer. The NTPA of the present invention has ultra-high active oxygen generation capacity, has great potential to fight multi-drug resistant bacteria and promote the healing of subcutaneous abscess wounds, and exhibits the most excellent photodynamic therapy performance. Under white light irradiation, its active oxygen production can be generated more than 470 times within 5 minutes. NTPA nanoparticles (NPs) show extremely high killing ability against various drug-resistant bacteria in vitro, and its in vitro antibacterial rate can reach 99.9%. It also shows its excellent bactericidal and wound healing ability at the living body level, and has great application prospects.

This invention discloses the use of a bacterial membrane dCACHE-type chemokine receptor protein family as a target in the preparation or screening of drugs against multidrug-resistant bacteria, belonging to the field of biomedical technology. This invention reveals and verifies for the first time the core regulatory mechanism of the dCACHE-type chemokine receptor protein family in the bacterial infection process: these proteins are key membrane surface receptors mediating bacterial chemotaxis towards macrophages; their loss of function can directly block bacterial chemotactic movement and significantly reduce pathogenicity. This invention, by targeting the conserved ligand binding interface, successfully inhibited the infectivity of drug-resistant pathogens such as *Yersinia pseudotuberculosis*, carbapenem-resistant *Acinetobacter baumannii*, and carbapenem-resistant *Escherichia coli*. The novel targeting strategy provided by this invention not only effectively overcomes the clinical bottleneck of "no available drugs" for carbapenem-resistant multidrug-resistant bacteria but also constructs a broad-spectrum protective barrier covering the entire homologous protein family, possessing extremely high clinical translational value and commercial development potential.

The present invention relates to an antibacterial composition. An antibacterial composition according to an embodiment of the present invention has an antibacterial effect against a multidrug-resistant strain, and comprises: a first antibacterial compound; a second antibacterial compound which is mixed with the first antibacterial compound and exhibits an antibacterial effect against the strain together with the first antibacterial compound; and a base compound which supports the first antibacterial compound and the second antibacterial compound, thereby maintaining the antibacterial activity thereof, wherein the first antibacterial compound is didecyldimethylammonium chloride (DDAC), and the second antibacterial compound is 3-(trimethoxysilyl)-propyldimethyloctadecyl ammonium chloride (Si-QAC).